The biggest development in single-molecule sequencing (aside from the steady improvement in PacBio's methods) is the arrival of the Oxford Nanopore devices on the market. These are also pretty rough around the edges, but they suggest a future in which labs have direct access to long-read, low-cost sequencing. Also, techniques like that from 10X genomics allow large-scale haplotype resolution, which is another missing component of a true "whole genome" sequence (humans and many other creatures have more than one different genome copy).
I think a lot of people do. Certainly I did, before I spent a year working in a genomics institute and had the opportunity for close observation of the massive uncertainty produced by short reads, and the concomitant complexity of the methods required to develop useful information from them.
At that time, long reads were just beginning to look reasonably attainable with new approached from Pacific Biosciences and other challengers to Illumina's market share; I'd be curious to know whether there's been any major movement in the half decade or so since I returned to industry.